7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2019-03-31 2018-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31 2009-12-31 2009-09-30 2009-06-30 2009-03-31 2008-12-31 2008-09-30 2008-06-30 2008-03-31 2007-09-30 2007-06-30 2007-03-31 2006-12-31 2006-09-30 2006-06-30 2006-03-31 2005-12-31 2005-09-30 2005-06-30 2005-03-31 2004-09-30 2004-06-30 2004-03-31 
      
    		                                                          
      operating activities:
    		                                                          
      net income
    		  -146,938,000 -104,349,000 -140,480,000 -66,265,000 -142,803,000 -9,263,000 -147,410,000 -85,290,000 -124,323,000 -52,430,000 -46,992,000 -105,135,000 -65,165,000 90,884,000 285,022,000 -26,676,000 -12,081,000 -31,280,000                                       
      adjustments to reconcile net income to net cash from operating activities:
    		                                                          
      depreciation
    		2,255,000 2,266,000 2,228,000 2,240,000 2,361,000 2,466,000 2,547,000 2,544,000 2,523,000 2,621,000 2,604,000 3,027,000 3,817,000 3,783,000 3,701,000 3,073,000 5,915,000 1,650,000 1,580,000 1,561,000                                       
      amortization of right-of-use operating lease assets
    		1,626,000 2,590,000 2,587,000 2,568,000 2,515,000 2,492,000 2,465,000 2,413,000 2,408,000 2,431,000 2,395,000 3,392,000 670,000 698,000 602,000                                            
      amortization of other assets
    		621,000 598,000 582,000 459,000 617,000 621,000 639,000 655,000 660,000 637,000 607,000                                                
      amortization of discount on investments
    		  -7,108,000  -9,140,000 -9,886,000 -9,257,000                                                    
      amortization of debt issuance costs
    		1,652,000 1,646,000 1,642,000 1,674,000 1,678,000 1,671,000 1,667,000 1,664,000 1,700,000 1,480,000 1,486,000 1,338,000 1,347,000 1,345,000 1,343,000 474,000 1,398,000 140,000 137,000 135,000                                       
      non-cash royalty revenue related to sale of royalties
    		  -12,891,000 -14,559,000 -14,186,000 -9,613,000 -6,623,000 -16,814,000 -15,252,000                                                  
      non-cash interest related to sale of future royalties
    		17,799,000 18,495,000 18,670,000 18,516,000 18,381,000 18,143,000 17,806,000 17,697,000 17,626,000 17,552,000 15,363,000                                                
      stock-based compensation expense
    		31,146,000 29,690,000 29,718,000 36,148,000 31,984,000 30,728,000 31,340,000 26,336,000 25,963,000 26,562,000 26,948,000 25,689,000 23,837,000 24,502,000 26,236,000 45,505,000 108,418,000 8,118,000 7,707,000 7,069,000                                       
      gain on investments
    		  1,849,000   3,533,000 -2,332,000   -830,000 529,000 -4,000 174,000 64,000 -10,000   -538,000 260,000 -397,000                                       
      non-cash losses related to other assets
    		 236,000 61,000 2,137,000 506,000 256,000 133,000 812,000 279,000 125,000 445,000                                                
      changes in operating assets and liabilities:
    		                                                          
      contracts receivable
    		27,972,000 -12,873,000 52,481,000 -74,260,000 9,331,000 -22,119,000 92,638,000 44,755,000 -114,560,000 -13,878,000 11,624,000 -18,893,000 106,000 19,371,000 35,774,000 4,908,000 62,806,000 15,628,000 -32,118,000 1,279,000                                       
      inventories
    		  1,010,000 -5,044,000 271,000 1,536,000 -1,834,000 -2,791,000 -96,000 -3,338,000 -167,000 -1,388,000 -834,000 4,221,000 774,000 -2,475,000 452,000 691,000 -239,000 496,000                                       
      other current and long-term assets
    		  -12,366,000 -17,702,000 1,226,000 -22,762,000 13,381,000 -11,515,000 1,371,000 -25,008,000 5,312,000 -23,694,000 -949,000 7,183,000 -7,222,000 1,802,000 -28,109,000 -545,000 202,000 -896,000                                       
      accounts payable
    		  -25,968,000 35,205,000 -2,151,000 -3,195,000 -13,869,000 20,581,000 -17,979,000 15,812,000 -10,295,000 -4,513,000 8,279,000 -5,550,000 2,878,000 -17,191,000 -2,069,000 -577,000 4,637,000 -2,646,000                                       
      income taxes
    		20,000 -45,000 92,000 -7,000 -243,000 -1,926,000 59,000                                                    
      accrued compensation
    		  -43,039,000 29,056,000 5,540,000 13,481,000 -46,190,000 33,946,000 4,459,000 11,162,000 -31,018,000 18,768,000 5,425,000 8,460,000 -22,285,000 -13,004,000 9,121,000 734,000 2,102,000 -7,840,000                                       
      accrued liabilities and other liabilities
    		                                                          
      deferred contract revenue
    		  -13,718,000 -14,301,000 -32,973,000 -62,727,000 -46,818,000 -61,784,000 103,446,000 -14,658,000 -13,037,000 -15,822,000 -14,422,000 -15,986,000 -25,018,000 -40,353,000 522,838,000 -9,606,000 -13,236,000 -5,742,000                                       
      net cash from operating activities
    		 151,338,000 -150,775,000 -116,139,000 -114,990,000 -119,880,000 -149,938,000 32,865,000 -109,022,000 -97,364,000 -133,992,000 -200,195,000 -24,429,000 -18,096,000 -31,650,000 107,705,000 667,287,000 1,944,000 -34,015,000 -32,328,000 -14,492,000 65,821,000 22,740,000 -10,576,000 36,035,000 -24,871,000 -2,577,000 -6,711,000  -24,448,000 -26,177,000 -39,842,000  -21,429,000 5,030,000 -21,691,000  -32,193,000 -10,370,000 -34,346,000 -19,176,000 -21,549,000 177,642,000 75,114,000 12,404,000 -1,371,000 -20,795,000    -16,063,000  -5,981,000 -19,360,000 -22,032,000 -22,089,000 -31,418,000 -23,467,000 
      capex
    		 0 -12,577,000 -25,497,000 -9,056,000 -6,234,000 -4,493,000 819,000 -2,141,000 -12,011,000 -10,472,000 -4,139,000 -5,542,000 -3,335,000 -2,705,000 -3,229,000 -9,639,000 -869,000 -1,697,000 -1,403,000 0 0 0 0 0 0 0 0  0 0 0  0 0 0  0 0 0 0 0 0 0 0 0 0    0  0 0 0 0 0 0 
      free cash flows
    		 151,338,000 -163,352,000 -141,636,000 -124,046,000 -126,114,000 -154,431,000 33,684,000 -111,163,000 -109,375,000 -144,464,000 -204,334,000 -29,971,000 -21,431,000 -34,355,000 104,476,000 657,648,000 1,075,000 -35,712,000 -33,731,000 -14,492,000 65,821,000 22,740,000 -10,576,000 36,035,000 -24,871,000 -2,577,000 -6,711,000  -24,448,000 -26,177,000 -39,842,000  -21,429,000 5,030,000 -21,691,000  -32,193,000 -10,370,000 -34,346,000 -19,176,000 -21,549,000 177,642,000 75,114,000 12,404,000 -1,371,000 -20,795,000    -16,063,000  -5,981,000 -19,360,000 -22,032,000 -22,089,000 -31,418,000 -23,467,000 
      investing activities:
    		                                                          
      purchases of short-term investments
    		  -311,068,000 -333,631,000 -715,360,000 -284,866,000 -519,001,000 -417,714,000 -420,738,000 -244,084,000 -688,278,000 -261,981,000 -560,596,000 -200,340,000 -462,855,000 -492,781,000 -1,544,155,000 -71,384,000 -110,011,000 -69,185,000                                       
      proceeds from sale of short-term investments
    		422,206,000 385,790,000 494,755,000 429,888,000 370,871,000 367,577,000 600,836,000 390,952,000 492,690,000 326,671,000 374,363,000 225,051,000 383,726,000 201,538,000 178,837,000                                            
      purchases of property, plant and equipment
    		  -12,577,000 -25,497,000 -9,056,000 -6,234,000 -4,493,000 819,000 -2,141,000 -12,011,000 -10,472,000 -4,139,000 -5,542,000 -3,335,000 -2,705,000 -3,229,000 -9,639,000 -869,000 -1,697,000 -1,403,000                                       
      acquisition of licenses and other assets
    		  -651,000 -2,547,000 12,750,000 -14,027,000 -1,237,000 -792,000 -1,100,000 -1,061,000 -1,253,000 -867,000 -1,518,000 -1,167,000 -826,000 -1,032,000 -1,601,000 -652,000 -1,458,000 -333,000                                       
      net cash from investing activities
    		91,338,000 -120,068,000 170,459,000 68,213,000 -340,795,000 62,450,000 76,105,000 -26,713,000 68,711,000 69,515,000 -325,640,000 212,147,000 -183,930,000 -3,304,000 -287,549,000 -70,174,000 -897,503,000 -24,487,000 -32,394,000 24,821,000     5,035,000 -10,608,000   33,963,000 -4,423,000 24,640,000 56,718,000 -7,242,000   14,958,000             9,178,000 1,017,000 13,338,000 -32,794,000 9,444,000 19,496,000 4,394,000 10,744,000 19,289,000 29,059,000 
      financing activities:
    		                                                          
      proceeds from issuance of common stock through equity plans
    		81,259,000 1,287,000 2,241,000 402,000                                                       
      proceeds from issuance of common stock in public offering
    		   27,000                                                       
      principal payments on mortgage debt
    		  -42,000 -41,000 -48,000 -39,000 -39,000  -47,000 -36,000 -39,000                                                
      net cash from financing activities
    		81,218,000 1,247,000 2,199,000 -44,116,000 496,047,000 2,557,000 23,570,000 40,724,000 -32,267,000 143,538,000 492,087,000 -51,019,000 1,834,000 1,215,000 -7,325,000 59,460,000 466,159,000 1,682,000 -1,288,000 9,312,000 3,327,000 17,355,000 197,992,000 9,050,000 -1,151,000 34,397,000       2,675,000 -401,000 2,354,000 68,000 2,708,000 5,127,000 835,000 193,331,000 9,318,000 2,150,000 25,166,000 70,951,000 12,802,000 -83,266,000 111,364,000 75,289,000 3,659,000 69,729,000 786,000 -2,410,000   2,394,000 2,420,000   
      effects of exchange rates on cash
    		-82,000 595,000 232,000 -486,000 350,000 -23,000 -114,000 330,000 -152,000 70,000 104,000 546,000 -399,000 -411,000 -154,000                                            
      net increase in cash and cash equivalents
    		41,037,000 33,112,000 22,115,000 -92,528,000 40,612,000 -54,896,000 -50,377,000 47,206,000 -72,730,000 115,759,000 32,559,000 -38,521,000 -206,924,000 -20,596,000 -326,678,000 96,991,000 235,943,000 -20,861,000 -67,697,000 1,805,000 -96,435,000 -40,132,000   39,919,000 -1,082,000     -1,178,000 16,148,000        30,072,000 -40,697,000 -181,038,000 173,784,000 133,322,000  -50,459,000 68,909,000 10,276,000 -1,121,000         6,640,000 
      cash and cash equivalents at beginning of period
    		0 0 242,077,000  0 0 399,266,000  0 0 276,472,000  0 0 869,191,000 278,820,000  0 0 159,973,000  0 0 124,482,000  0 0 65,477,000  0 0 70,052,000  0 0 105,255,000  0 0 223,985,000  0 0 138,614,000     0 47,235,000 3,650,000  0 0 27,250,000 0 0 33,117,000 
      cash and cash equivalents at end of period
    		41,037,000 33,112,000 264,192,000  40,612,000 -54,896,000 348,889,000  -72,730,000 115,759,000 309,031,000  -206,924,000 -20,596,000 542,513,000 375,811,000  -20,861,000 -67,697,000 161,778,000  -40,132,000 188,890,000 107,650,000  -1,082,000 29,254,000 56,391,000  -29,759,000 -1,178,000 86,200,000  54,084,000 -52,552,000 98,590,000  -66,496,000 -38,268,000 254,057,000  -181,038,000 173,784,000 271,936,000       1,711,000  45,234,000 -4,018,000 12,006,000 -8,925,000 -9,386,000 39,757,000 
      supplemental disclosures of cash flow information:
    		                                                          
      interest paid
    		185,000 5,122,000 92,000  145,000 5,474,000 95,000  423,000 440,000 89,000  660,000 950,000 594,000 667,000  57,000 2,837,000 83,000  102,000 2,864,000 113,000  3,309,000 64,000 2,211,000 157,000 2,249,000 123,000 2,275,000 195,000 2,281,000 132,000 2,281,000 217,000 2,270,000 146,000 2,250,000 125,000 2,174,000 64,000 2,244,000 2,606,000 2,521,000 860,000 3,778,000 381,000 3,863,000 409,000 3,859,000 516,000 3,980,000 522,000 333,000 3,955,000 570,000 
      income taxes paid (refunds received)
    		                                                          
      supplemental disclosures of non-cash investing and financing activities:
    		                                                          
      right-of-use assets obtained in exchange for lease obligations
    		79,686,000                                                          
      amounts accrued for capital and patent expenditures
    		333,000 -315,000 460,000  787,000 529,000 924,000  90,000 -2,807,000 3,058,000  1,911,000 -223,000 1,344,000 1,864,000  2,751,000 -1,053,000 1,506,000  -220,000 340,000 715,000  160,000 -165,000 844,000 -476,000 298,000 -142,000 1,222,000 -5,000 96,000 -5,000 836,000 -370,000 326,000 -4,102,000 5,016,000 216,000 1,190,000 95,000 1,372,000 -519,000 101,000 443,000            
      loss on investments
    		   2,572,000                                                       
      accrued liabilities and other current liabilities
    		 3,202,000 333,000 -14,332,000 10,540,000 3,686,000 -42,887,000 18,713,000 13,343,000 -9,102,000 -28,460,000 8,432,000 -6,907,000 34,697,000 10,473,000                                            
      income taxes paid
    		  -400,000  80,000 1,979,000 13,000  204,000 217,000 293,000  0 0 2,000       0 0 2,000      0 0 2,000  0 0 7,700,000 3,000,000 3,400,000 6,455,000 350,000                   
      amortization of premium (discount) on investments
    		       -8,489,000 -7,915,000 -7,439,000 -5,042,000                                                
      gain on early retirement of debt
    		       0 -2,097,000                                                  
      non-cash losses related to disposal of property, plant and equipment
    		   7,290,000    2,003,000 14,441,000   3,000 1,000 0 527,000                                            
      gain on sale of real estate assets
    		                                                          
      proceeds from sale of real estate assets
    		                                                          
      repayment of 0.125 percent convertible senior notes
    		                                                          
      proceeds from issuance of 1.75 percent convertible senior notes
    		       0 0                                                  
      1.75 percent convertible senior notes issuance costs
    		       0 -517,000                                                  
      proceeds from sale of future royalties
    		       0 0 0 500,000,000                                                
      payments of transaction costs related to sale of future royalties
    		       0 0 0 -10,434,000                                                
      proceeds from real estate transaction
    		       0                                                   
      payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options
    		           -736,000 -645,000 -399,000 -9,173,000                                            
      cash and cash equivalents at beginning of year
    		                                                          
      cash and cash equivalents at end of year
    		                                                          
      repurchase of 504.4 million principal amount of 0.125 percent convertible senior notes
    		       0                                                   
      proceeds from equity
    		     2,596,000 23,609,000 40,762,000 3,730,000 2,390,000 2,560,000 343,000 2,568,000 1,614,000 1,848,000                                            
      repurchase of 434.1 million principal amount of 0.125 percent convertible senior notes
    		                                                          
      purchases of strategic investments
    		                                                          
      proceeds from the issuance of 0 percent convertible senior notes
    		                                                          
      0 percent convertible senior notes issuance costs
    		                                                          
      repurchase of 247.9 million principal amount of 1 percent convertible senior notes
    		                                                          
      repayment of remaining principal amount of 1 percent convertible senior notes at maturity
    		                                                          
      proceeds from issuance of warrants
    		                                                          
      purchase of note hedges
    		                                                          
      principal payments on debt
    		                                                          
      income taxes payable
    		        6,338,000 7,446,000 11,037,000  2,000                                              
      right-of-use assets obtained in exchange for lease liabilities
    		               13,557,000                                           
      amortization of premium on investments
    		           -1,683,000 1,205,000 3,692,000 4,175,000 -2,433,000  1,802,000 2,471,000 1,376,000                                       
      loss on early retirement of debt
    		                                                          
      deferred income taxes, including changes in valuation allowance
    		                                                          
      long-term income taxes receivable
    		                                                          
      royalty monetization issuance costs
    		                                                          
      repurchases and retirements of common stock
    		                                                          
      purchase of noncontrolling interest of akcea therapeutics, inc., including cash payments for cancellation of akcea therapeutics, inc. equity awards
    		                                                          
      amortization of patents
    		            608,000 605,000 592,000 470,000 981,000 298,000 280,000 263,000                                       
      non-cash losses related to patents
    		            204,000 841,000 110,000                                            
      purchase of bicycle therapeutics plc common stock
    		                                                          
      proceeds from the issuance of 0 percent convertible notes
    		                                                          
      repurchase of 247.9 million principal amount of the 1 percent convertible senior notes
    		                                                          
      income taxes receivable
    		              865,000                                            
      amortization of convertible senior notes discount
    		               8,726,000                                           
      non-cash losses related to patents, licensing and property, plant and equipment
    		               14,000  428,000 217,000 108,000                                       
      benefit from deferred income taxes
    		               13,549,000                                           
      accrued liabilities and deferred rent
    		               13,756,000                                           
      proceeds from the sale of short-term investments
    		               426,868,000 659,928,000 47,119,000 80,489,000 95,288,000 37,632,000 38,204,000 47,850,000 49,076,000 53,262,000 46,716,000 80,900,000 61,781,000 117,046,000 73,695,000 127,849,000 170,328,000 94,057,000 181,203,000 143,652,000 158,621,000 138,181,000 182,281,000 159,451,000 98,973,000 153,724,000 19,499,000 30,093,000 62,635,000 27,778,000 44,617,000 24,481,000 12,575,000 20,050,000 16,950,000 23,000,000 13,435,000 8,590,000 19,203,000 8,985,000 33,921,000 44,566,000 64,181,000 
      proceeds from equity awards
    		               67,057,000  4,293,000 1,413,000 12,003,000 6,060,000 20,019,000                                     
      payments of tax withholdings related to vesting of employee stock awards
    		               -7,597,000                                           
      offering costs paid
    		                                                          
      amortization of long-term financing liability for leased facility
    		                 1,656,000 1,654,000 1,652,000                                       
      gain on investment in regulus therapeutics inc.
    		                                                          
      loss on extinguishment of financing liability for leased facility
    		                                                          
      deferred income taxes
    		                                                          
      non-cash losses related to patents, licensing, property, plant and equipment and strategic investments
    		                                                          
      long-term income tax receivable
    		                                                          
      purchase of strategic investments
    		                                                          
      proceeds from the sale of regulus therapeutics, inc.
    		                                                          
      proceeds from issuance of common stock in akcea therapeutics, inc. from its initial public offering, net of underwriters’ discount
    		                                                          
      proceeds from building mortgage debt, net of issuance costs
    		                                                          
      proceeds from the issuance of common stock to biogen
    		                                                          
      proceeds from the issuance of common stock to novartis
    		                                                          
      proceeds from borrowing on line of credit facility
    		                                                          
      proceeds from the sale of akcea therapeutics, inc. common stock to novartis in a private placement
    		                                                          
      payment to settle financing liability for leased facility
    		                                                          
      excess tax benefits from stock-based compensation awards
    		                                                          
      principal payments on debt and capital lease obligations
    		                 -2,611,000 -2,701,000 -2,691,000                                       
      amortization of licenses
    		                 471,000 470,000 471,000                                       
      amortization of 23¤4 percent convertible senior notes discount
    		                 1,737,000                                         
      deferred rent
    		                 57,000 44,000 25,000                                       
      accrued liabilities
    		                 5,081,000 -678,000 2,643,000                                       
      proceeds from the sale of strategic investments
    		                 1,299,000 283,000 454,000                 0 0       0 2,936,000 2,245,000            
      net proceeds from public common stock offering
    		                     69,000                                     
      proceeds from equipment financing arrangement
    		                    0 0   0 0   0 0   1,611,000 0   0 3,689,000 0 2,705,000                   
      tax benefit from other unrealized gains on securities
    		                  881,000 -2,276,000                                       
      amortization of 2¾ percent convertible senior notes discount
    		                   1,671,000                                       
      amortization of 25¤8 percent convertible subordinated notes discount
    		                                                          
      share-based compensation expense
    		                                                          
      equity in net income of regulus therapeutics inc.
    		                                                          
      investment in regulus therapeutics inc.
    		                                                          
      proceeds from issuance of 23¤4 percent convertible senior notes, net of issuance costs
    		                                                          
      principal and premium payment on redemption of the 25¤8 percent convertible subordinated notes
    		                                                          
      proceeds from public common stock offering
    		                                                          
      proceeds from sale of strategic investments
    		                     172,000 844,000 1,094,000                                   
      proceeds from issuance of 2¾ percent convertible senior notes, net of issuance costs
    		                                                          
      principal and premium payment on redemption of the 25/8 percent convertible subordinated notes
    		                                                          
      proceeds from issuance of equity
    		                       11,823,000 1,681,000 6,172,000 979,000 638,000 2,013,000 678,000                             
      net decrease in cash and cash equivalents
    		                                                          
      amortization of 25/8 percent convertible subordinated notes discount
    		                                                          
      amortization of 23¤4 percent convertible subordinated notes discount
    		                                                          
      gain from the sale of property, plant and equipment
    		                                                          
      (gain) loss on investments
    		                                                          
      proceeds from the sale of property, plant and equipment
    		                                                   5,814,000 7,041,000 1,000,000 165,000    
      proceeds from land sold to biomed
    		                                0 0 0 10,147,000                       
      reduction of cash due to deconsolidation of regulus therapeutics inc. upon adoption of a new accounting standard
    		                                                          
      capitalized costs and financing liability associated with leased facility
    		                            982,000 10,173,000                             
      gain from sale of ibis biosciences, inc. to abbott molecular inc.
    		                                                          
      excess tax benefits on share-based compensation
    		                                                          
      purchases of strategic investments, net of proceeds received
    		                                                          
      proceeds from sale of ibis biosciences, inc to abbott molecular inc.
    		                                                          
      proceeds from alnylam’s capital contribution to regulus therapeutics inc.
    		                                    0 0 0 10,000,000                   
      income taxes paid, net of refund received
    		                                                          
      capital lease obligations
    		                                                          
      principal payments on debt obligations
    		                                                          
      net proceeds from issuance of equity
    		                               683,000 2,320,000 754,000 251,000 1,031,000 3,361,000 2,168,000 1,484,000 6,143,000 2,171,000 5,819,000 1,997,000 2,727,000 4,650,000 684,000 1,188,000 77,343,000 5,620,000 670,000 2,731,000 -1,000 48,797,000 19,000 353,000 743,000 401,000 2,172,000 
      supplemental disclosures of non-cash investing activities:
    		                                                          
      loss attributed to noncontrolling interest in ibis biosciences, inc.
    		                                                          
      gain from derivative instruments issued to abbott molecular inc.
    		                                                          
      proceeds from issuance of convertible promissory note to glaxosmithkline
    		                                                          
      proceeds from stock purchase by genzyme corporation, net of fees
    		                                        0 0 0 49,962,000               
      cash and cash equivalents (including cash and cash equivalents classified as assets from discontinued operations of 0, 0 and 6.1 million at december 31, 2010, 2009 and 2008, respectively) at end of year
    		                                                          
      proceeds from sale of ibis biosciences, inc. to abbott molecular inc.
    		                                     0 0 175,000,000                   
      non-cash losses related to patents and property, plant and equipment
    		                                                          
      acquisition of symphony genisis, inc.
    		                                                          
      proceeds from issuance of 25/8 percent convertible subordinated notes, net of issuance costs
    		                                                          
      principal and redemption premium payment on prepayment of the 51/2 percent convertible subordinated notes
    		                                                          
      cash and cash equivalents (including cash and cash equivalents classified as assets from discontinued operations of 0, 6.1 million and 0 at december 31, 2009, 2008 and 2007, respectively) at end of year
    		                                                          
      common stock issued for symphony genisis, inc. acquisition
    		                                                          
      proceeds from issuance of convertible promissory note to gsk
    		                                         0                 
      loss attributed to noncontrolling interest in symphony genisis, inc.
    		                                                          
      loss attributed to noncontrolling interest in regulus therapeutics inc.
    		                                                          
      inventory
    		                                                          
      deferred contract revenues
    		                                                          
      purchase of short-term investments
    		                                                          
      proceeds from issuance of 25/8% convertible subordinated notes, net of issuance costs
    		                                                          
      principal and redemption premium payment on prepayment of the 51/2% convertible subordinated notes
    		                                                          
      proceeds from capital contributions to ibis biosciences, inc.
    		                                        0 0                 
      proceeds from capital contribution to regulus therapeutics inc.
    		                                                          
      proceeds from contribution to noncontrolling interest in symphony genisis, inc., net of fees
    		                                                          
      cash and cash equivalents (including cash and cash equivalents classified as assets held for sale of 6.1 million, 0 and 0 at december 31, 2008, 2007 and 2006, respectively) at end of year
    		                                                          
      warrant issued in conjunction with symphony genisis, inc. transaction
    		                                               0 0          
      acquisition of property, plant and equipment
    		                                                          
      proceeds from capital contribution to regulus therapeutics llc
    		                                                          
      proceeds from issuance of 25¤8% convertible subordinated notes, net of issuance costs
    		                                              157,067,000            
      proceeds from capital contribution to ibis biosciences, inc.
    		                                           20,000,000               
      proceeds from issuance of 2 5/8% convertible subordinated notes, net of issuance costs
    		                                                          
      principal and redemption premium payment on prepayment of the 5 1/2% convertible subordinated notes
    		                                                          
      proceeds from purchase of noncontrolling interest in symphony genisis, inc, net of fees
    		                                                          
      cash and cash equivalents (including cash and cash equivalents held by symphony genisis, inc. of 54.8 million and 0 at december 31, 2006 and 2005, respectively) at beginning of period
    		                                            0 0 114,514,000            
      cash and cash equivalents (including cash and cash equivalents held on behalf of regulus therapuetics llc of 10.0 million at september 30, 2007 and 58.6 million held by symphony genisis, inc. at september 30, 2006) at end of period
    		                                                          
      cash and cash equivalents (including cash and cash equivalents held by symphony genisis, inc. of 43.0 million and 64.4 million at june 30, 2007 and 2006, respectively) at end of period
    		                                                          
      cash and cash equivalents (including cash and cash equivalents held by symphony genisis, inc. of 49.6 million and 0 at march 31, 2007 and 2006, respectively) at end of period
    		                                              183,423,000            
      amortization of (discount)/premium on investments
    		                                                          
      compensation benefit related to variable accounting of stock options
    		                                                          
      deferred interest on long-term debt
    		                                                          
      (gain)/loss on investments
    		                                                          
      non-cash restructuring activities
    		                                                          
      non-cash losses related to patents and fixed assets
    		                                                          
      income from variable accounting of stock warrants
    		                                                          
      gain on disposal of property, plant and equipment
    		                                                          
      strategic investments in corporate securities
    		                                                          
      proceeds from long-term borrowing
    		                                                          
      cash and cash equivalents (including cash and cash equivalents held by symphony genisis, inc. of 54.8 million, 0 and 0 at december 31, 2006, 2005 and 2004, respectively) at end of year
    		                                                          
      conversion of receivables into long-term investment
    		                                                          
      conversion of debt into common stock
    		                                                   0       
      conversion of preferred stock into common stock
    		                                                       1,000   
      purchase of property, plant and equipment
    		                                                          
      other assets
    		                                                          
      strategic investments
    		                                                0          
      proceeds from long-term borrowings
    		                                                    -397,000 0 5,000,000 4,169,000 4,999,000 7,574,000 
      proceeds from purchase of noncontrolling interest in symphony genisis, inc., net of fees
    		                                                          
      cash and cash equivalents (including cash and cash equivalents held by symphony genisis, inc. of 58.6 million and 0 at september 30, 2006 and december 31, 2005, respectively) at end of period
    		                                                          
      cash and cash equivalents (including cash and cash equivalents held by symphony genisis, inc. of 64.4 million and 0 at june 30, 2006 and december 31, 2005, respectively) at end of period
    		                                                          
      compensation (benefit) related to stock options
    		                                                          
      licenses and other assets
    		                                                          
      investments in affiliates
    		                                                          
      conversion of contract receivable into long-term investment
    		                                                          
      additions to long-term investments for acquired corporate securities
    		                                                          
      decrease in inventory and deferred revenue
    		                                                          
      decrease in property, plant and equipment and notes payable
    		                                                          
      common stock warrants
    		                                                          
      supplemental disclosures of non-cash financing activities:
    		                                                          
      net cash provided from financing activities
    		                                                         1,048,000 
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.